Targeting isocitrate dehydrogenase-1 (IDH1) and IDH2 mutations. Clinical results in advanced hematologic malignancies

Date 04 March 2015
Event 13th International Congress on Targeted Anticancer Therapies
Session Targeting cancer metabolic dysfunction
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Haematologic Malignancies
Presenter Stephane de Botton